# US 2022/0054406 A1 · Composition and method for treatment of diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0054406 A1
- Document ID: US20220054406A1
- Status: Published application
- Kind: A1
- Application number: 17/518,939
- Filed: 2021-11-04
- Published: 2022-02-24
- Earliest claimed: 2009-01-12
- Assignees: BioKier, Inc.
- Applicants: BioKier, Inc.
- Inventors: Jerzy Ryszard Szewczyk
- Web page: https://patentgrep.com/patent/US20220054406A1

## CPC

- A61K 9/0031: {Rectum, anus}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/195: having an amino group
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K 9/0004: {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of treating diabetes Type II by oral delivery of butyric acid, and a DPP-IV inhibitor such as vildagliptin only to the ileum bypassing the stomach, duodenum and jejunum.

## Claims

### Claim 1 (depends on 1)

An oral pharmaceutical composition for use in a human comprising:
composition for use in a human comprising:
a) a single agent for inducing release of a gut hormone from an L-cell, wherein the single agent is butyric acid in an amount from about 100 mg to about 2 gm; and
b) a DPP-IV inhibitor of from about 0.01 mg/kg to about 1 mg/kg in an amount that is about 1% to about 10% of the oral dosage of the DPP-IV inhibitor normally delivered to the stomach of the human, sufficient to inhibit the degradation of the gut hormone in the ileum and in the portal circulation;
wherein the agent and the inhibitor are formulated together for simultaneous delivery to and release in the ileum using a ileum-targeted delivery system which bypasses the stomach, duodenum and jejunum upper digestive system. The composition according to claim 1 wherein the DPP-IV inhibitor is selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, linagliptin, dutogliptin, gemigliptin, alogliptin, and berberine.

### Claim 2 (depends on 1)

The composition according to claim 1 wherein the gut hormone is selected from the group consisting of GLP-1, GLP-2, PYY, and oxyntomodulin.

### Claim 3

In another embodiment of the present invention, there is a method of treating the condition of diabetes mellitus Type II in a human comprising:
a) selecting a single agent causing gut hormone secretion from L-cells, wherein the agent is butyric acid in an amount from about 100 mg to about 2 gm;
b) selecting a DPP-IV inhibitor of from about 0.01 mg/kg to about 1 mg/kg consisting of an amount that is from about 1% to about 10% of the oral dosage of the DPP-IV inhibitor delivered to the stomach sufficient to inhibit the degradation of the gut hormone in the ileum and in the portal circulation; and
c) administering to the individual the agent formulated in combination with the DPP-IV inhibitor orally using a ileum-targeted delivery system, which bypasses the stomach, duodenum and jejunum and causes simultaneous ileum delivery and release of the agent and inhibitor.

### Claim 4 (depends on 4)

The method according to claim 4 wherein the DPP-IV inhibitor is selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, linagliptin, dutogliptin, gemigliptin, alogliptin, and berberine.

### Claim 5 (depends on 5)

The method according to claim 5 wherein the inhibitor is vildagliptin.
